# Tuvusertib in Astrocytoma With ATRX Mutation

> **NCT07417761** · PHASE2 · RECRUITING · sponsor: **Grupo Español de Investigación en Neurooncología** · enrollment: 56 (estimated)

## Conditions studied

- Astrocytoma

## Interventions

- **DRUG:** Tuvusertib

## Key facts

- **NCT ID:** NCT07417761
- **Lead sponsor:** Grupo Español de Investigación en Neurooncología
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-19
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07417761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07417761, "Tuvusertib in Astrocytoma With ATRX Mutation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07417761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*